Press Release



www.shire.com

Director/PDMR Shareholding

20 December, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG)

Notification of transactions by persons discharging managerial responsibilities

1.	Details of the person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA")		
a)	Name	Susan Kilsby	
2.	Reason for the notificati	on	
a)	Position / status	Chairman – PDMR	
b)	Initial notification / amendment	Initial notification	
3.	Details of the issuer, em auction monitor	ission allowance participant, au	ction platform, auctioneer or
a)	Name	Shire plc	
b)	LEI	54930005LQRLI2UXRQ59	
4.		n(s): section to be repeated for (i) each type of instrument; (ii) ; (iii) each date; and (iv) each place where transactions have	
a)	Description of the financial instrument, type of instrument	Shire plc American Depositary Sl	hares ("ADSs")
	Identification code	ISIN: US82481R1068	
b)	Nature of the transaction	Acquisition of ADSs, being the parare paid in ADSs for the period of December 31, 2018.	
٥)	Drigg(a) and value a(a)	Price(s)	Volume(s)
c)	Price(s) and volume(s)	\$168.0470	164
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)	
e)	Date of the transaction	December 19, 2018	
f)	Place of the transaction	XNAS / XBOS / ARCX	

1.	Details of the person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA")		
a)	Name	Olivier Bohuon	
2.	Reason for the notificati	on	
a)	Position / status	Senior Independent Director - PDMR	
b)	Initial notification / amendment	Initial notification	
3.	Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor		
a)	Name Shire plc		
b)	LEI	54930005LQRLi2UXRQ59	

4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument Shire plc Ordinary Shares of 5 pence each ("Ordinary Shares of 5 pence each ("Ord		ence each ("Ordinary Shares")
	Identification code	ISIN: JE00B2QKY057	
b)	Nature of the transaction	Acquisition of Ordinary Shares, being the part of Mr. Bohuon's total fees that are paid in Ordinary Shares for the period of service from October 1 to December 31, 2018.	
۵)	Dring(a) and values a(a)	Price(s)	Volume(s)
c)	Price(s) and volume(s)	£44.31	140
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)	
e)	Date of the transaction	December 19, 2018	
f)	Place of the transaction	LSE (TRQX)	

1.	Details of the person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA")		
a)	Name	Ian Clark	
2.	Reason for the notificati	on	
a)	Position / status	Non-Executive Director - PDMR	
b)	Initial notification / amendment	Initial notification	
3.	Details of the issuer, em auction monitor	ission allowance participant, au	ction platform, auctioneer or
a)	Name	Shire plc	
b)	LEI	54930005LQRLI2UXRQ59	
4.		n(s): section to be repeated for (i) each type of instrument; (ii); (iii) each date; and (iv) each place where transactions have	
a)	Description of the financial instrument, type of instrument	Shire plc American Depositary Sh	nares ("ADSs")
	Identification code	ISIN: US82481R1068	
b)	Nature of the transaction	Acquisition of ADSs, being the parare paid in ADSs for the period of December 31, 2018.	
۵)	Dring(a) and values a(a)	Price(s)	Volume(s)
c)	Price(s) and volume(s)	\$168.0470	44
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)	
e)	Date of the transaction	December 19, 2018	
f)	Place of the transaction	XNAS / XBOS / ARCX	

1.	Details of the person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA")	
a)	Name	Gail Fosler

2.	Reason for the notification			
a)	Position / status	Non-Executive Director - PDMR	Non-Executive Director - PDMR	
b)	Initial notification / amendment	Initial notification	Initial notification	
3.	Details of the issuer, em auction monitor	ission allowance participant, au	ction platform, auctioneer or	
a)	Name	Shire plc		
b)	LEI	54930005LQRLI2UXRQ59		
4.		n(s): section to be repeated for (i) each type of instrument; (ii); (iii) each date; and (iv) each place where transactions have		
a)	Description of the financial instrument, type of instrument	Shire plc American Depositary Sh	nares ("ADSs")	
	Identification code	ISIN: US82481R1068		
b)	Nature of the transaction	Acquisition of ADSs, being the part of Ms. Fosler's total fees that are paid in ADSs for the period of service from October 1 to December 31, 2018.		
- \	D: ()	Price(s)	Volume(s)	
c)	Price(s) and volume(s)	\$168.0470	47	
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)		
e)	Date of the transaction	December 19, 2018		
f)	Place of the transaction	XNAS / XBOS / ARCX		

1.	Details of the person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA")		
a)	Name	Steven Gillis	
2.	Reason for the notification	on	
a)	Position / status	Non-Executive Director - PDMR	
b)	Initial notification / amendment	Initial notification	
3.	Details of the issuer, em auction monitor	ission allowance participant, aud	ction platform, auctioneer or
a)	Name	Shire plc	
b)	LEI	54930005LQRLI2UXRQ59	
4.		n(s): section to be repeated for (i) each type of instrument; (ii) (iii) each date; and (iv) each place where transactions have	
a)	Description of the financial instrument, type of instrument	Shire plc American Depositary Shares ("ADSs")	
	Identification code	ISIN: US82481R1068	
b)	Nature of the transaction	Acquisition of ADSs, being the part of Dr. Gillis' total fees that are paid in ADSs for the period of service from October 1 to December 31, 2018.	
6)	Drigg(s) and volume(s)	Price(s)	Volume(s)
c)	Price(s) and volume(s)	\$168.0470	49

d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)
e)	Date of the transaction	December 19, 2018
f)	Place of the transaction	XNAS / XBOS / ARCX

1.	Details of the person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA")			
a)	Name	David Ginsburg	David Ginsburg	
2.	Reason for the notificati	on		
a)	Position / status	Non-Executive Director - PDMR		
b)	Initial notification / amendment	Initial notification		
3.	Details of the issuer, em auction monitor	ission allowance participant, aud	ction platform, auctioneer or	
a)	Name	Shire plc		
b)	LEI	54930005LQRLI2UXRQ59		
4.		n(s): section to be repeated for (i) each type of instrument; (ii); (iii) each date; and (iv) each place where transactions have		
Description of the financial instrument, type of instrument Shire plc American Depositary Shares ("A financial instrument")		nares ("ADSs")		
	Identification code	ISIN: US82481R1068		
b)	Nature of the transaction	Acquisition of ADSs, being the parthat are paid in ADSs for the period December 31, 2018.		
۵)	Drice (a) and value o(a)	Price(s)	Volume(s)	
c)	Price(s) and volume(s)	\$168.0470	44	
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)		
e)	Date of the transaction	December 19, 2018		
f)	Place of the transaction	XNAS / XBOS / ARCX		

1.	Details of the person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA")	
a)	Name	Sara Mathew
2.	Reason for the notifica	ition
a)	Position / status	Non-Executive Director - PDMR
b)	Initial notification / amendment	Initial notification
3.	Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor	
a)	Name	Shire plc
b)	LEI	54930005LQRLI2UXRQ59
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the	Shire plc American Depositary Shares ("ADSs")

	financial instrument, type of instrument		
	Identification code	ISIN: US82481R1068	
b)	Nature of the transaction	Acquisition of ADSs, being the part of Ms. Mathew's total fees that are paid in ADSs for the period of service from October 1 to December 31, 2018.	
۵)	Drice (e) and values o(e)	Price(s)	Volume(s)
(c)	Price(s) and volume(s)	\$168.0470	46
	Aggregated information	N/A (single transaction)	
d)	- Aggregated volume		
	- Price		
e)	Date of the transaction	December 19, 2018	
f)	Place of the transaction	XNAS / XBOS / ARCX	

1.	Details of the person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA")		
a)	Name	Albert Stroucken	
2.	Reason for the notificati	on	
a)	Position / status	Non-Executive Director - PDMR	
b)	Initial notification / amendment	Initial notification	
3.	Details of the issuer, em auction monitor	ission allowance participant, au	ction platform, auctioneer or
a)	Name	Shire plc	
b)	LEI	54930005LQRLI2UXRQ59	
4.		n(s): section to be repeated for (i) each type of instrument; (ii); (iii) each date; and (iv) each place where transactions have	
a)	Description of the financial instrument, type of instrument	Shire plc American Depositary Shares ("ADSs")	
	Identification code	ISIN: US82481R1068	
b)	Nature of the transaction	Acquisition of ADSs, being the part of Mr. Stroucken's total fees that are paid in ADSs for the period of service from October 1 to December 31, 2018.	
۵)	Drice (a) and values a (a)	Price(s)	Volume(s)
c)	Price(s) and volume(s)	\$168.0470	63
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)	
e)	Date of the transaction	December 19, 2018	
f)	Place of the transaction	XNAS / XBOS / ARCX	

Sarah Rixon Senior Company Secretarial Assistant

For further information please contact:

Investor Relations

 Sun Kim
 sun.kim@shire.com
 +1 617 588 8175

 Scott Burrows
 scott.burrows@shire.com
 +41 41 288 4195

Media

Katie Joyce kjoyce@shire.com +1 781 482 2779

NOTES TO EDITORS

About Shire

Shire is the global biotechnology leader serving patients with rare diseases and specialized conditions. We seek to push boundaries through discovering and delivering new possibilities for patient communities who often have few or no other champions. Relentlessly on the edge of what's next, we are serial innovators with a diverse pipeline offering fresh thinking and new hope. Serving patients and partnering with healthcare communities in over 100 countries, we strive to be part of the entire patient journey to enable earlier diagnosis, raise standards of care, accelerate access to treatment, and support patients. Our diverse portfolio of therapeutic areas includes Immunology, Hematology, Genetic Diseases, Neuroscience, Internal Medicine, and Ophthalmics.

Championing patients is our call to action - it brings the opportunity - and responsibility - to change people's lives.

www.shire.com